Supplementary Online Content


**eFigure.** Quantification of AR-FL and AR-V7 transcript levels in CTCs from metastatic CRPC patients initiating treatment with taxane chemotherapy

This supplementary material has been provided by the authors to give readers additional information about their work.
**eFigure.** Quantification of AR-FL and AR-V7 transcript levels in CTCs from metastatic CRPC patients initiating treatment with taxane chemotherapy

Absolute transcript copy numbers of AR-FL and AR-V7 detected in circulating tumor cells (CTCs) are shown for the 17 taxane-treated patients who were positive for AR-V7 at baseline (i.e. in their pretreatment CTC samples). Ratios of AR-
V7/AR-FL are expressed as percentages above each bar. AR-FL levels are also shown for the AR-V7–negative samples. In addition, there were 6 patients (not shown) who were negative for AR-FL, all of which were also negative for AR-V7. Detection of AR-V7 was associated with increased expression of AR-FL ($P<0.001$).